Compare Levi Strauss & Co. (LEVI) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Levi Strauss & Co. vs GeneDx Holdings Corp — how do they compare? Levi Strauss & Co. trades at $22.49 (market cap $8.75B), while GeneDx Holdings Corp trades at $82.69 (market cap $2.44B). The key difference: Levi Strauss & Co. is far larger — about 3.6× GeneDx Holdings Corp's market cap, and Levi Strauss & Co. pays a 2.81% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| LEVI | WGS | |
|---|---|---|
Market Cap | $8.75B | $2.44B |
Sector | Consumer Cyclical | Technology |
52-Week High | $25.53 | $167.51 |
52-Week Low | $17.92 | $34.51 |
Enterprise Value | $10.07B | $2.48B |
Dividend Yield | 2.81% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Levi Strauss & Co. (LEVI) trades at $23.59, down 3.32% over 24 hours, amid a recent cybersecurity incident disclosed on August 7, 2026. The stock shows strong fundamentals with a P/E of 16.24, robust gross margin of 61.72%, and consistent earnings beats in recent quarters. Technical indicators are bearish, with support near $23, while analyst consensus remains bullish with a $27.88 price target.
The outlook for LEVI is positive due to solid DTC growth and raised 2026 guidance, but risks include cybersecurity concerns and tariff pressures. Earnings momentum and a reasonable valuation support upside potential, though near-term volatility may persist from the security breach and market reactions.
GeneDx Holdings Corp (WGS) trades at $82.36, up 5.75% in 24 hours, with a bullish technical signal and strong analyst support. Recent Q2 2026 results beat expectations with $0.01 EPS and record testing volumes, though net income margins remain negative. The stock faces class action litigation risks but benefits from institutional buying and new product launches.
Outlook is mixed: bullish technicals and 91% buy ratings suggest upside to the $90 high target, but negative profitability and legal overhangs pose risks. Investors should weigh growth potential against financial sustainability and litigation outcomes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Levi Strauss & Co.
Levi Strauss & Co is involved in designing, marketing, and selling products that include jeans, casual and dresses pants, tops, shorts, skirts, jackets, footwear, and related accessories directly or through third parties and licensees for men, women, and children under Levi's, Dockers, Signature by Levi Strauss & Co. and Denizen brands. The company manages its business according to three regional segments: the Americas, which is the key revenue driver
Read more on LEVI →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
